<?xml version="1.0" encoding="UTF-8"?>
<p id="p0080">Recently, a synthetic flavagline developed by the eFFECTOR Therapeutics company, Zotatifin (also called eFT226, 
 <bold>4</bold>, 
 <xref rid="fig1" ref-type="fig">Fig.Â 1</xref>) has entered a phase 1/2 clinical trial against advanced solid tumors refractory or intolerant to standard treatments [
 <xref rid="bib19" ref-type="bibr">19</xref>]. While it was shown to inhibit eIF4A, its putative effect on PHB signaling has not yet been disclosed. A first description of the structure-activity relationships of flavaglines for the inhibition of eIF4A was disclosed in 2012 and 2014 [
 <xref rid="bib33" ref-type="bibr">33</xref>,
 <xref rid="bib34" ref-type="bibr">34</xref>]. This model was more recently refined by Porco, Pelletier and collaborators [
 <xref rid="bib35" ref-type="bibr">[35]</xref>, 
 <xref rid="bib36" ref-type="bibr">[36]</xref>, 
 <xref rid="bib37" ref-type="bibr">[37]</xref>] and also by eFFECTOR scientists [
 <xref rid="bib20" ref-type="bibr">20</xref>].
</p>
